0001415889-25-017917.txt : 20250620 0001415889-25-017917.hdr.sgml : 20250620 20250620210506 ACCESSION NUMBER: 0001415889-25-017917 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250616 FILED AS OF DATE: 20250620 DATE AS OF CHANGE: 20250620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sheena Jonathan CENTRAL INDEX KEY: 0001646649 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37478 FILM NUMBER: 251062778 MAIL ADDRESS: STREET 1: NATERA, INC. STREET 2: 13011 MCCALLEN PASS, BLDG A, STE 100 CITY: AUSTIN STATE: TX ZIP: 78753 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Natera, Inc. CENTRAL INDEX KEY: 0001604821 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 010894487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 BUSINESS PHONE: 650-249-9090 MAIL ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 4 1 form4-06202025_090601.xml X0508 4 2025-06-16 0001604821 Natera, Inc. NTRA 0001646649 Sheena Jonathan C/O NATERA, INC. 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 true false false true CO-FOUNDER 1 Common Stock 2025-06-18 4 S 0 3070 167.2869 D 248774 D Common Stock 2025-06-16 4 S 0 200 162.4968 D 38582 I By Caraluna 1 Trust Common Stock 2025-06-16 4 S 0 203 163.4069 D 38379 I By Caraluna 1 Trust Common Stock 2025-06-16 4 S 0 550 164.8073 D 37829 I By Caraluna 1 Trust Common Stock 2025-06-16 4 S 0 547 165.4829 D 37282 I By Caraluna 1 Trust Common Stock 2025-06-16 4 S 0 176 162.5178 D 38606 I By Caraluna 2 Trust Common Stock 2025-06-16 4 S 0 200 163.10 D 38406 I By Caraluna 2 Trust Common Stock 2025-06-16 4 S 0 425 164.6398 D 37981 I By Caraluna 2 Trust Common Stock 2025-06-16 4 S 0 699 165.4079 D 37282 I By Caraluna 2 Trust The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.7250 to $167.6950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.04 to $162.58 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.12 to $163.66 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.45 to $165.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.48 to $165.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.04 to $162.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.08 to $163.12 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.10 to $165.01 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.16 to $165.55 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Tami Chen, Attorney-in-Fact 2025-06-20